Clone ranger Sphere Fluidics riding high with FairJourney Biologics deal

Cambridge life science company Sphere Fluidics has been chosen by a world-leading antibody specialist for an exciting new initiative.

FairJourney Biologics in Portugal has adopted Sphere’s Cyto-Mine® platform as part of the launch for its latest cell line development services to streamline and accelerate customer workflows.

Sphere Fluidics is scaling impressively by developing single cell analysis systems underpinned by its patented picodroplet technology; the FairJourney Biologics deal is a significant endorsement of the technology.

The Portuguese company is a world leading end-to-end antibody partner providing integrated services across antibody discovery, engineering, and production.

Cyto-Mine’s advanced features, such as selection of producer clones, monoclonality assurance, significant time savings, flexible assay designs, GLP compliance support, and regulatory compatibility, seamlessly complement FairJourney Biologics’ services – providing partners with comprehensive and efficient solutions for their R & D endeavours.

Traditional processes for finding novel antibody targets or developing stable cell lines are typically time-consuming, often inefficient, and difficult to scale.

Cyto-Mine is an automated platform which integrates single cell screening, sorting, dispensing, imaging and clone verification, with proof of monoclonality.

Underpinned by Sphere’s patented technology, it provides an integrated system with an easy-to-use and intuitive interface that can automatically, yet gently, screen up to 40 million cells in a matter of hours, compared to 10,000 typically achieved using multi-step manual techniques.

This accelerated throughput is already widely recognised across a variety of research areas, including antibody discovery, cell line development, cell engineering and synthetic biology.

The platform also facilitates rapid, high-throughput single cell manipulation and analysis across an expanding range of emerging research areas, including precision genome editing, cell therapy research and cellular diagnostics.

FairJourney Biologics’ partners will also benefit from the Cyto-Mine’s recent software updates supporting FDA 21 CFR Part 11 compliance and including a full Installation Qualification/Operation Qualification package for pharmaceutical quality assurance, extending the system’s applications into drug manufacturing operations.